April 29 (Reuters) - The CEO of Novartis said

on Tuesday that the Swiss drugmaker is investing in the United

States to no longer rely on dedicated production capacity in

Europe and other regions that would serve the U.S., its biggest

market.

"We now want to ensure that 100% of the demand of our key

products in the U.S. is produced in the U.S.," CEO Vas

Narasimhan said, declining to provide details on volumes.

Novartis said this month it plans to spend $23 billion

to build and expand 10 facilities in the U.S., as it grapples

with renewed threats of drug import duties from the Trump

administration.